tokens: BACKGROUND : A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 %) and renal insufficiency ( 0 %). Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .